Therapy Areas: AIDS & HIV
Janssen Data Support Switch to Symtuza (D/C/F/TAF) HIV-1 Treatment and Use in a Rapid Initiation Scenario
26 July 2018 - - Janssen Pharmaceutical Companies, a segment of US-based global healthcare company Johnson and Johnson (NYSE: JNJ), has presented new data at the at AIDS 2018 conference reinforcing the safety and efficacy of switching to Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg; D/C/F/TAF) for the treatment of human immunodeficiency virus type 1 (HIV-1) regardless of prior treatment regimen among treatment-experienced patients, the company said.
Data presented from another Phase 3 study also provide evidence to support a darunavir-based regimen when rapidly initiating treatment in people who are newly diagnosed with HIV-1.
Results from EMERALD showed similar virologic response rates at Week 48 (HIV-1 RNA
Login
Username:

Password: